Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/28924
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBanstola, A-
dc.contributor.authorAnokye, N-
dc.contributor.authorPokhrel, S-
dc.date.accessioned2024-05-03T12:40:31Z-
dc.date.available2024-05-03T12:40:31Z-
dc.date.issued2024-05-02-
dc.identifierORCiD: Amrit Banstola https://orcid.org/0000-0003-3185-9638-
dc.identifierORCiD: Nana Anokye https://orcid.org/0000-0003-3615-344X-
dc.identifierORCiD: Subhash Pokhrel https://orcid.org/0000-0002-1009-8553-
dc.identifiere0301485-
dc.identifier.citationBanstola, A., Anokye, N. and Pokhrel, S. (2024) 'The economic burden of multimorbidity: Protocol for a systematic review', PLOS ONE, 19 (5), e0301485 , pp. 1 - 10. doi: 10.1371/journal.pone.0301485.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/28924-
dc.descriptionData Availability: No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.en_US
dc.descriptionSupporting information is available online at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0301485#sec019 .-
dc.description.abstractMultimorbidity, also known as multiple long-term conditions, leads to higher healthcare utilisation, including hospitalisation, readmission, and polypharmacy, as well as a financial burden to families, society, and nations. Despite some progress, the economic burden of multimorbidity remains poorly understood. This paper outlines a protocol for a systematic review that aims to identify and synthesise comprehensive evidence on the economic burden of multimorbidity, considering various definitions and measurements of multimorbidity, including their implications for future cost-of-illness analyses. The review will include studies involving people of all ages with multimorbidity without any restriction on location and setting. Cost-of-illness studies or studies that examined economic burden including model-based studies will be included, and economic evaluation studies will be excluded. Databases including Scopus (that includes PubMed/MEDLINE), Web of Science, CINAHL Plus, PsycINFO, NHS EED (including the HTA database), and the Cost-Effectiveness Analysis Registry, will be searched until March 2024. The risk of bias within included studies will be independently assessed by two authors using appropriate checklists. A narrative synthesis of the main characteristics and results, by definitions and measurements of multimorbidity, will be conducted. The total economic burden of multimorbidity will be reported as mean annual costs per patient and disaggregated based on counts of diseases, disease clusters, and weighted indices. The results of this review will provide valuable insights for researchers into the key cost components and areas that require further investigation in order to improve the rigour of future studies on the economic burden of multimorbidity. Additionally, these findings will broaden our understanding of the economic impact of multimorbidity, inform us about the costs of inaction, and guide decision-making regarding resource allocation and cost-effective interventions. The systematic review’s results will be submitted to a peer-reviewed journal, presented at conferences, and shared via an online webinar for discussion.en_US
dc.description.sponsorshipThe author(s) received no specific funding for this work. This study is part of the first author's PhD project and that the first author is sponsored by the Department of Health Sciences at Brunel University London.en_US
dc.format.extent1 - 10-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherPublic Library of Science (PLoS)en_US
dc.rightsCopyright: © 2024 Banstola et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectshystematic reviewsen_US
dc.subjecthealth economicsen_US
dc.subjectdatabase searchingen_US
dc.subjectsocioeconomic aspects of healthen_US
dc.subjectfinanceen_US
dc.subjectmedical risk factorsen_US
dc.subjecteconomicsen_US
dc.subjectpublic and occupational healthen_US
dc.titleThe economic burden of multimorbidity: Protocol for a systematic reviewen_US
dc.typeArticleen_US
dc.date.dateAccepted2024-03-16-
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0301485-
dc.relation.isPartOfPLOS ONE-
pubs.issue5-
pubs.publication-statusPublished online-
pubs.volume19-
dc.identifier.eissn1932-6203-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dc.rights.holderBanstola et a;.-
Appears in Collections:Dept of Health Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright: © 2024 Banstola et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.292.8 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons